PUBLISHER: DelveInsight | PRODUCT CODE: 1226628
PUBLISHER: DelveInsight | PRODUCT CODE: 1226628
"LATUDA Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LATUDA for Bipolar Depression (BD) in the United States, and Japan. A detailed picture of the LATUDA for Bipolar Depression in the United States, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LATUDA for Bipolar Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LATUDA market forecast analysis for Bipolar Depression in the United States, and Japan descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Bipolar Depression.
LATUDA (Lurasidone Hydrochloride) is an oral tablet containing lurasidone hydrochloride as an active ingredient. It is approved in the United States for bipolar depression in pediatric patients (10-17 years old) and schizophrenic patients (adolescent and adult) as monotherapy and as adjunctive therapy in adult bipolar depression patients. In the EU, it is only approved for the treatment of schizophrenia, whereas in Japan, it is approved for both schizophrenia and bipolar disorder. Moreover, Lupin Pharma gained approval for a generic version of Sunovion Pharmaceuticals' LATUDA. However, under the terms of an agreement between generic drug makers and LATUDA's manufacturer, generic versions of the drug will not become available currently.
Lurasidone is a benzothiazole derivative and a second-generation (atypical) antipsychotic. Like other atypical antipsychotics, it antagonizes dopamine D2 receptors and serotonin 5-HT2A and 5-HT7 receptors. It is a partial agonist at 5-HT1A receptors. In addition, it antagonizes adrenergic alpha2A and alpha2C receptors but exhibits minimal affinity for histaminic (H1) and acetyl cholinergic muscarinic (M1) receptors. Modulation of serotonin, norepinephrine, and dopamine is the cornerstone of antidepressant pharmacotherapy. Lurasidone may exert antidepressant effects by increasing dopamine activity in the prefrontal cortex through activity at 5-HT2A and 5-HT1A receptors. It may enhance serotonin activity by downregulating 5-HT2A receptors. In addition, it may increase norepinephrine by antagonizing alpha1 receptors. Antagonism of 5-HT7 receptors may improve mood. The FDA has tentatively approved a generic version of LATUDA in the US.
The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated by combining central dopamine D2 and serotonin type 2 (5-HT2A) receptor antagonism.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
LATUDA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of LATUDA for Bipolar Depression in the United States, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of LATUDA for Bipolar Depression covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions